Mineralys Therapeutics, Inc.
MLYS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $31 | $38 | $38 | $45 |
| G&A Expenses | $10 | $8 | $7 | $7 |
| SG&A Expenses | $10 | $8 | $7 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $41 | $47 | $44 | $52 |
| Operating Income | -$41 | -$47 | -$44 | -$52 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | $3 | $2 | $3 |
| Pre-Tax Income | -$37 | -$43 | -$42 | -$49 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$37 | -$43 | -$42 | -$49 |
| % Margin | – | – | – | – |
| EPS | -0.52 | -0.66 | -0.79 | -0.98 |
| % Growth | 21.2% | 16.5% | 19.4% | – |
| EPS Diluted | -0.52 | -0.66 | -0.79 | -0.98 |
| Weighted Avg Shares Out | 71 | 65 | 53 | 50 |
| Weighted Avg Shares Out Dil | 71 | 65 | 53 | 50 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $3 | $2 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$37 | -$47 | -$44 | -$52 |
| % Margin | – | – | – | – |